Chargement en cours...
Are we ready to use biomarkers for staging, prognosis and treatment selection in early-stage non-small-cell lung cancer?
Lung cancer accounts for the majority of cancer-related deaths worldwide. At present, platinum-based therapy represents the standard of care in fit stage II and IIIA non-small cell lung cancer (NSCLC) patients following surgical resection. In advanced disease, personalized chemotherapy and targeted...
Enregistré dans:
| Publié dans: | Transl Lung Cancer Res |
|---|---|
| Auteurs principaux: | , , , , |
| Format: | Artigo |
| Langue: | Inglês |
| Publié: |
Pioneer Bioscience Publishing Company
2013
|
| Sujets: | |
| Accès en ligne: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4367596/ https://ncbi.nlm.nih.gov/pubmed/25806234 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3978/j.issn.2218-6751.2013.03.06 |
| Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|